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Abstract
Pregnant and parenting women with opioid use disorder face multiple challenges to
recovery. Trauma histories, poverty, stigma and discrimination, and lack of access to treatment
intersect to marginalize this population. It is important that pregnant and parenting women with
opioid use disorder receive comprehensive care to improve their health, the health of their
child(ren), and prevent the intergenerational transmission of opioid and other substance use
disorders. For nearly 50 years the Maternal Addiction Treatment, Education, and Research
program has provided an evolving and expanding range of comprehensive services for treating
opioid and other substance use disorders in this population. In this review the rationale for, and
processes by which, key components of a comprehensive approach are discussed. These
components include patient navigation for access to care, low-barrier medications for opioid use
disorder, effective trauma-responsive therapy, prenatal and well-child healthcare, and other
support services that make it possible for pregnant and parenting women to engage in treatment
and improve the health of the entire family. Additionally, a method for supporting staff to build
resilience and reduce fatigue and burnout is discussed. These components comprise an
effective model of care for pregnant and parenting women with opioid and other substance use
disorders.
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Introduction
The United States’ ongoing overdose crisis claimed over 67,000 lives in 2018, with
opioids involved in nearly 70% of deaths (Wilson et al., 2020). Opioid use disorder (OUD) has
historically been less prevalent among women, but increased at a faster rate among women
compared to men between 2002-2013 (C. M. Jones et al., 2015). Among pregnant women, the
prevalence of OUD at delivery increased fourfold between 1999-2014 (Haight et al., 2018).
Within a similar timeframe (1999-2013), the incidence of neonatal abstinence syndrome (NAS)
concomitantly increased from 1.5 to 6.0 per 1000 births (Ko et al., 2016). After delivery, rates of
maternal overdose increase substantially through 12 months postpartum (Schiff et al., 2018).
Treatment for OUD among reproductive-aged women must be responsive to differing needs
across life stages due to the significant rates and impacts of OUD before and after pregnancy.
Furthermore, a comprehensive response that addresses factors that underlie OUD and other
substance use disorders (SUDs) is necessary to promote whole-person wellness, build
resilience in families, and prevent intergenerational transmission of SUDs.
The ongoing crisis is occurring within a context of trauma history, stigma and
discrimination, and the effects of toxic stress. Adverse childhood experiences (ACEs) are known
to be associated with poor health outcomes in adults and are highly prevalent among women
with SUDs (Gannon et al., 2020). Women who use substances face stigma and discrimination in
healthcare, criminal justice, and social welfare arenas (Stone, 2015). The intersection of the
experiences of trauma and stigma affect treatment adherence and recovery.
Treatment for OUD has become more widely available. There have been increases in
federally licensed opioid treatment programs that provide medications for OUD (mOUD) and
related services, such as expansions of waivers for clinicians to prescribe buprenorphine. While
mOUD is a critical part of treatment for pregnant and parenting women with OUD, there are life
factors that enable or challenge treatment adherence. Comprehensive services that address
poverty, trauma, and advocacy are necessary to improve the health of the mother-infant dyad
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and broader family. Comprehensive treatment and support services for women with children
may have a “treatment as prevention” effect by disrupting intergenerational transmission of
ACEs and thus reducing the likelihood that children will develop poor health and SUDs in
adulthood.
Comprehensive treatment for OUD among pregnant and parenting women must address
poverty, education, and other socioeconomic factors in addition to treatment that is informed by
trauma-responsiveness, stress reduction, and state-of-the-art substance use disorder therapy.
Over the last five decades, the Maternal Addiction Treatment, Education, and Research
(MATER) program’s comprehensive approach to treating OUD among pregnant and parenting
women has evolved and grown to move toward holistically meeting these needs. MATER
provides OUD treatment and comprehensive healthcare and psychosocial services in both
outpatient and residential settings that serve approximately 350 pregnant and parenting women
each year. A transdisciplinary team of patient navigators, peer specialists, therapists, nurses,
nurse practitioners, physicians of various specialties, childcare workers, and others provides
coordinated wrap-around services (Figure 1). At the center of care are providing mOUD and
offering trauma-responsive therapy, with patient navigation assisting with entrance into
treatment and continued engagement in core and additional support services. The entire team,
including support staff, receives continuous active support to cultivate compassion toward
patients, colleagues, and themselves, and promote effective self-care using Mindfulness-Based
Stress Reduction as a framework. The Mindfulness Dialogue for Life program for all staff and
leadership, which involves weekly reflections, group guided meditation, and group discussion
aimed at connecting, exploring, and discovering, has been useful for staff in managing the
regular stresses of such difficult work and added stress related to the COVID-19 pandemic
(Abatemarco et al., 2021). The present review describes the rationale for essential components
in a model of comprehensive care, including patient navigation, mOUD, therapy, healthcare
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services, and support services for parents, supporting staff wellness, and the processes by
which each is delivered at MATER.

Compassion as a Foundation
Compassion is an awareness of suffering with a desire to reduce that suffering. Whereas
empathy involves awareness of suffering, compassion goes a step further toward alleviating
suffering. When directed toward others, compassion embodies the idea of “meeting the person
where they are,” as a construct, greater self-compassion is associated with lower risk of SUD
(Phelps et al., 2018). Compassion-focused therapy, which is explicitly aimed at fostering selfcompassion, is feasible and acceptable for individuals with OUD (Carlyle et al., 2019). Further, it
is a critical component in providing mindful and person-centered care. Compassion as a tenet of
care influences each component of comprehensive OUD treatment, beginning with a person’s
entry into care and continued engagement.

Patient Navigation - Entering and Continued Engagement in Care
Pregnancy is a unique period of increased motivation and opportunity for women with
OUD. While not every woman chooses to continue a pregnancy or to parent, those that do are
often strongly motivated to seek treatment in an effort to protect the health of themselves and
their babies (Frazer et al., 2019). The desire to protect the pregnancy leads to more futureoriented thinking around parenting goals. Acknowledging that complex trauma histories and
experience of stigmatization and discrimination challenge interacting with medical systems, a
compassionate and low-barrier approach to initiating care is essential.
Low-barrier access to mOUD has proven a highly efficient method for engaging women
in treatment. For some, self-initiation onto buprenorphine prescribed with minimal additional
services is effective (Lee et al., 2014). Others may need a full opioid agonist like methadone
and more structured and coordinated services to meet their goals. Methadone initiation can be
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less accessible due to needing to meet regulatory criteria for treatment and requirements for
daily attendance and monitoring to titrate dosing. For pregnant individuals, MATER offers
continuous access to immediate evaluation and initiation onto mOUD through our affiliated
academic medical center’s inpatient obstetrics unit. A 3-5 day inpatient admission offers a
unique opportunity to rapidly initiate an agonist medication, assess urgent maternal-fetal
medical concerns, and in conjunction with MATER’s Patient Navigation Team guide women to
needed treatment and recovery supports. MATER’s Patient Navigation Team utilizes
hospitalization, a time of both increased motivation and decreased distraction, to provide
comprehensive care coordination toward each individual’s treatment goals.
The Patient Navigation team operates on foundational principles of compassion, dignity,
and respect. Motivational Interviewing tenets of relationship building, open-ended questions,
active and reflective listening, and client-driven goal-setting guide care coordination. These
tenets dually inform interactions with both clients and providers. Navigators meet with each
patient to build a relationship and discuss personal needs and goals. This collaborative, patientdriven needs assessment helps to identify an individualized treatment path and plan to enter
treatment post-hospitalization. Navigators and patients converse and reflect on elements of past
treatment that were helpful (if applicable), barriers to treatment, goals, and individual strengths;
this reflection is essential to engagement in structured treatment and recovery.
As additional supports, navigators provide each person with a welcome kit that includes
items like a mindfulness journal, daily planner, and general activity books. The journals and
daily planners begin laying the groundwork for recovery behaviors, such as developing coping
skills through journaling, brief mindfulness practice, and creating daily plans. Activity books
afford opportunities to engage in alternative behaviors during an abrupt change from OUDrelated behaviors and to mitigate boredom. In addition, navigators obtain other items requested
by individuals after the first encounter, which have included yoga mats, preferred shampoo, and
clothing items.

Comprehensive Response for Parents with OUD

7

As the relationship between a patient and a navigator strengthens over the
hospitalization, navigators connect individuals to treatment. Based on an individual’s goals and
life circumstances, navigators identify treatment options and discuss details of the options with
patients. Navigators engage and empower individuals during the entire process. One example
of this is by facilitating phone calls with programs so individuals can ask questions directly to
providers to foster a sense of partnership and ownership over their own process. Additionally,
navigators work to address barriers to treatment like problem-solving childcare concerns,
planning transportation, and confidentiality with their family. From 2017-2021, 773 individuals
with OUD received Patient Navigation services and 73% began treatment for OUD. Of those,
75% entered treatment at MATER’s programs, and 25% entered other programs due to
differences in patient needs, goals, and insurance coverage.
For those individuals entering treatment at MATER’s programs, navigators are a bridge
into care at MATER. Navigators provide orientation and scheduling of the first weeks of
treatment, using planners from the welcome kit. Once discharged from the hospital, the
navigator continues to work alongside the patient. The navigator provides the patient with a tour
of the MATER facility, introduces them to staff with whom they will most often interact, and
walks them through medicating processes. The navigator also completes intake with the client.
As intake procedures can be extremely personal and include intimate information, the
relationship built between patient and navigator can help the patient be more comfortable during
this period of vulnerability. The transition to attending and engaging in a comprehensive daily
structure of treatment requires many levels of behavior change. Navigators practice sensitivity
and compassion as they accompany clients through the transition into treatment and recovery.
Navigators remain a member of each patient’s treatment team. Each navigator partners
with a counselor, who will be the primary therapeutic support person for the patient, and the pair
continue to work closely with the patient. Having built a trusting relationship with the patient, the
navigator introduces the patient to the counselor and the three conduct a joint initial session, if
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appropriate. Alternatively, a communicated utilization of transitive trust such as “you trust me, I
trust this counselor, therefore you can trust this counselor” can help ease the transition. As
treatment continues, navigators meet with patients at least once a month to maintain their
relationship, evaluate care coordination needs, provide emotional and advocacy support.
Navigators track engagement daily by reviewing medication dispensing logs and through
communication with counselors and other staff. Navi

Medications for Opioid use Disorder in Pregnancy
The benefits of agonist medications for OUD, methadone and buprenorphine, are well
established for pregnant and non-pregnant individuals. Opioid agonist medication continues to
be the recommended pharmacotherapy by leading professional and public health organizations
(ACOG Committee on Health Care for Underserved Women & American Society of Addiction
Medicine, 2012; Kampman & Jarvis, 2015). Withdrawal management alone is not recommended
due to high occurrence of return to use (Terplan et al., 2018). Extended release naltrexone is
currently being studied for its effectiveness and safety in pregnancy. The two opioid agonist
medications each have benefits and limitations. Given differing regulatory structures and
insurance handling, the medication choice often dictates the type of support services and overall
treatment structure that is available to the person. During the above-described hospitalization
for stabilization, the patient, Patient Navigation team, and physicians engage in shared decisionmaking in selecting the mOUD most likely to meet the patient’s needs.

Methadone
Methadone is a full opioid agonist with a long history of use for OUD. Being a full agonist
with a long half life, a single daily dose of methadone can be beneficial for individuals with high
opioid tolerance. Methadone is also available in liquid formats that allow doses to be finely
tailored to a person’s needs. It is also potentially more dangerous because it can cause
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somnolescene and because full agonists have higher overdose risks. When titrated to an
appropriate dose that reduces withdrawal and cravings, methadone prevents additional opioid
use from producing effects, and produces minimal somnolescence, methadone is a safe
medication.
During pregnancy, many individuals experience changes in how their bodies metabolize
methadone. These changes can affect the amount of methadone needed to achieve
pharmacological effectiveness and how long each dose prevents withdrawal and cravings.
Methadone doses should be increased, as needed, to prevent withdrawal and cravings in
pregnant individuals. There is no consistent association between higher maternal methadone
doses and increased risk of neonatal abstinence syndrome (NAS) (Berghella et al., 2003;
Cleary et al., 2010; McCarthy et al., 2005).
Splitting the maternal daily dose of methadone during pregnancy into two or more doses
throughout the day is an effective means for managing increases in methadone metabolism and
may reduce the risk of NAS. Many pregnant individuals experience an increase in methadone
metabolism. Increased methadone metabolism may cause withdrawal symptoms to arise before
the next day’s dose. Providing multiple doses of methadone can prevent cycling between
effective management and withdrawal. In one study among pregnant individuals who received
split doses of methadone, NAS requiring pharmacotherapy occurred 29% of the time vs. 6080% in the literature of individuals receiving daily doses (McCarthy et al., 2015). Methadone
metabolism returns to pre-pregancy rates rapidly following the end of pregnancy (McCarthy et
al., 2018).
By regulation, methadone may only be dispensed for treating OUD by federally
approved opioid treatment programs (OTPs). The regulations under which OTPs operate can
help to reduce safety risks, such as requiring licensed staff to dispense medication, ensuring
careful measurement of methadone doses that are dispensed, and requiring individuals to be
observed taking their medication. These regulations also require that OTPs provide support
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services and therapy. The requirements of daily dispensing and mandatory therapy can be
barriers to this level of care for some individuals and may give others the accountability and
structure needed to support their recovery.

Buprenorphine
Buprenorphine is a partial opioid agonist and antagonist at different opioid receptor
types. Buprenorphine’s opioid effects reach a ceiling that limits its overdose potential.
Buprenorphine may be prescribed for treating OUD by specially licensed prescribers, including
physicians and advanced practice providers, or dispensed from OTPs, which can make it a
more accessible medication for OUD. In the context of pregnancy, buprenorphine is equally
effective to methadone for treating OUD and may be associated with lower NAS severity (H. E.
Jones et al., 2010, 2012). The diminishing effectiveness of increasing doses of buprenorphine
may be problematic for individuals with high opioid tolerance, and self-managed dosing can be
difficult for some individuals’ recovery.
For non-pregnant individuals, buprenorphine is usually taken as a single daily dose, like
methadone. Also like methadone, pregnancy causes changes in buprenorphine metabolism that
often require repeated dosing throughout the day based on an assumed effective plasma
concentration of 1ng/mL (Caritis et al., 2017). Long-acting injectables and implants that release
doses over time are currently being evaluated for safety and efficacy in pregnancy.
There has been debate whether mono-product buprenorphine or dual-product buprenorphine
plus naloxone is most appropriate in pregnancy, given some early safety concerns regarding
naloxone in pregnancy. A recent meta-analysis found no significant adverse effects of the dualproduct in pregnancy and significantly reduced incidence of NAS among infants whose mothers
received the dual-product (Link et al., 2020). The product used should match the person’s
response but may be influenced by state or insurance policies that mandate mono- or dualproducts.
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Overall, both methadone and buprenorphine are effective and safe medications for
OUD. Individuals may have better responses to one or the other, and there is some evidence
that buprenorphine products may be associated with less severe neonatal withdrawal.
Unfortunately, these medications and comprehensive care are not equally available. Medication
costs may be a significant barrier for OTPs as buprenorphine products are many times more
expensive than methadone. Individuals receiving care at OTPs are at a disadvantage for
receiving what may be a more beneficial medication for them. Individuals who receive
buprenorphine from office-based providers may not have access to the same wrap-around
services that are available through OTPs. Softening of regulations for OTPs, alignment of
methadone and buprenorphine regulations and insurance policies about medication use,
equitable funding for OTPs to provide all medications for OUD, and integration of wraparound
services across all OUD treatment settings are needed to minimize disparities in access and
effectiveness of services.

Therapy and Trauma Responsiveness
Most people with OUD benefit from receiving evidence-based therapy. Therapy provided
in individual or group modalities has long been a cornerstone of OUD treatment, and there is
growing evidence and support for including family members in these therapeutic services
(Rowe, 2012). For pregnant and parenting women with OUD, therapy effectiveness is enhanced
when gender-specific services are provided, particularly when addressing acute and chronic
trauma (Greenfield et al., 2007). Psychoeducational interventions provided in group format are
also beneficial when tailored to the specific needs of the population, such as around parenting,
child care, and physical health.
A majority of women with OUD have experienced trauma, including ACEs. Within a
sample of 152 women receiving treatment at MATER, 65% reported experiencing 4 or more
ACEs, and only 5% reported experiencing none (Gannon et al., 2020). Responses to such a
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high prevalence of trauma must occur at multiple levels and involve a programmatic approach
that includes trauma-focused therapy along with other practices to prevent perpetuating
additional trauma. Group-based therapeutic interventions that address trauma and are specific
to the needs of women with trauma histories include the Trauma Recovery and Empowerment
Model (TREM) (Fallot & Harris, 2002) and Seeking Safety (Najavits, 2002). Both TREM and
Seeking Safety are manualized interventions with known efficacy in helping to increase feelings
of safety and may reduce drug use (Bailey et al., 2019).
Broader programmatic changes to be trauma-responsive are also critical. Most SUD
treatment programs require urine drug testing, often under conditions of observation. Urine drug
testing can be a useful tool for providing objective feedback to person on their recovery. Many
find this feedback particularly motivating to achieving a goal of abstinence, especially when
combined with reinforcement as in contingency management (Hand, Ellis, et al., 2017;
Ledgerwood & Petry, 2006; Walter & Petry, 2016). However, it can be a source of harm in
damaging a clinician-individual trust, and the mere act of being observed by another person
while urinating is traumatizing for some (Khatri & Aronowitz, 2020). Other organizational factors
that may cause re-traumatization include security controls, medication denial, and the stigma
associated with engaging in SUD treatment. Organizational approaches to traumaresponsiveness, such as Mindfulness Based Stress Reduction training or the Sanctuary Model
may be helpful at minimizing re-traumatization in addition to creating a safe and welcoming
space for all individuals regardless of trauma histories.
Therapeutic staff should also be knowledgeable about all substances as they frequently
must address polysubstance use. Over 60% of pregnant women entering treatment for OUD
report using two or more substances, primarily benzodiazepines, cocaine, and cannabis (Hand,
Short, et al., 2017). Use of other drugs, especially cocaine, increases risk of early treatment
discontinuation, making therapy aimed at reducing other drug use especially important (Levine
et al., 2015).
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The setting and intensity of services should be flexible to meet a person’s needs. A
single institution that offers multiple levels of care within the American Society of Addiction
Medicine’s continuum can help individuals receive different frequencies and types of services
under a single guiding set of principles. Only 15% of facilities report having specialized
treatment for pregnant and postpartum women, and only 19% of those offer child care (Terplan
et al., 2015). With so few SUD treatment options available that serve pregnant and parenting
women and their needs, it is unlikely that a pregnant or parenting person will have access to
multiple levels of care across different organizations.

Support Services for Parents
The inclusion of additional support services is also an important component of
comprehensive treatment for pregnant and parenting women with OUD. Services that facilitate
engagement in therapy can help retention and can be areas to foster additional growth. Child
care is chiefly important, especially when parents are engaging in therapy or psychoeducational
sessions. Co-located child care with OUD treatment services can also be leveraged to provide
connection and engagement in early intervention programs, including Head Start. These
facilities can also be safe places to facilitate parent-child play and to assist interventions directly
focused on improving the quality of parenting and mother-child attachment.
The mother-child dyad relationship is uniquely challenged by a mother’s journey in her
recovery. This population of mothers faces multiple barriers to recovery and healthy living
including unemployment, homelessness, domestic violence, incarceration, and physical and
mental health problems (Skinner et al., 2011). Compared to parenting women without OUD,
they often experience higher levels of stress (Bagner et al., 2009), more depressive symptoms
(Liles et al., 2012), guilt associated with their drug use (Silva et al., 2013), fear of losing custody
of their child (Marsh et al., 2011),and feelings of being a failure (Sheinkopf et al., 2006). While
individual barriers to treatment include fears around child protective services involvement or the

Comprehensive Response for Parents with OUD

14

loss of custody, there are also systems-level barriers to treatment: only 26% of drug courts allow
pregnant women to be treated with buprenorphine or methadone (Hall et al., 2016). The
complex synergy of challenges facing women in treatment for OUD can ultimately lead to
maladaptive attachment in the dyad, which is critical as the mother child attachment bond is the
single most significant relationship the child endures through adolescence (Collins & Laursen,
2004).
Parenting deficits have long been known and studied in this population (Suchman &
Luthar, 2000, 2001). Behaviors involved in, or associated with, acquiring, using, and recovering
from the effects of substances, may lead to a parent to act distant or less engaged in their
child’s development (Salo & Flykt, 2013). Complex post-traumatic stress, which is prevalent
among women with SUDs, increase difficulties in bonding and attachment (Schwerdtfeger &
Goff, 2007). Attachment, bonding, and positive parenting are essential to support women
through the difficult recovery processes and to protect the infant and prevent intergenerational
transmission of trauma. Early childhood experiences of trauma are prevalent in this population,
at a substantially higher rate than the general population (Gannon et al., 2020).
Given this prevailing data on the lived experience of trauma for these mothers, as well
as the parenting challenges they face, MATER developed a trauma-responsive Mindfulness
Based Parenting (MBP) program. MBP engages women to bring a sense of intentional
attention to the newborn, and other children, without judgement. MBP is a way of enhancing
self-compassion that is then integrated with parenting to foster intentional compassion to one’s
children. MBP is provided as a group therapy session at MATER, with curriculum spread
across 2-hour sessions each week over 13 weeks. Each weekly session includes a meditative
practice, mindful movement, didactic piece around mindfulness and child development,
discussion and inquiry over patterns of behavior and experience, and experiential mindful play
with their children. The MBP program has been shown to increase positive parenting behaviors
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(Gannon et al., 2017), and decrease parental stress (Short et al., 2017) and post-partum
depression (Alexander et al., 2019).

Support Services for Families
Recognizing that many ACEs and other traumatic events are shared among family,
MATER has begun expanding mindfulness-based support services to family members. This
transformative project, funded by SAMHSA, involves expanding the lessons learned from the
development of MBP to help heal family relationships among individuals in MATER’s residential
treatment program. Mindfulness-based family support, family therapy, and linkage to community
supports during and continuing after residential treatment are aimed at fostering a community
support system that includes the family. This family engagement can also support maintenance
of intact maternal-child dyads or aid in reunification of mothers with their children who have
been placed in protective care. This is critical as data shows that parents with custodial rights of
their children have more successful recovery, than those without custodial rights (Comiskey,
2013). Interim analyses have revealed eagerness of family members to engage in these
services, as exemplified by most individuals having family members attend biweekly family
dinners, high utilization of home visiting services, and engagement in MBP. The research
component of this project is scheduled to be completed in 2023.

Prenatal Care
Prenatal care (PNC) is essential for healthy pregnancies. Women in SUD treatment may
not have supportive partners during pregnancy/labor/post-partum and may not have consistent
exposure to education around pregnancy, birth, and taking care of a newborn. Adequate PNC
provides screening for and management of risk factors and health conditions, and education
and counseling on healthy behaviors. Adequate PNC may be especially important for women
with OUD given the prevalence of risk factors and health conditions often associated with poor
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perinatal outcomes, including unplanned pregnancies (Heil et al., 2011), co-occurring mental
health conditions (e.g., stress, anxiety, depression) (Holbrook & Kaltenbach, 2012; Le Strat et
al., 2011), cigarette smoking (H. E. Jones et al., 2009), polysubstance use, and trauma history
(Gannon et al., 2020). For women with OUD, PNC should be co-managed by obstetricians,
gynecologists, and addiction medicine specialists, and coordinated with pediatric providers postdelivery for the care of in utero exposed infants. In the absence of other medical indications,
more intensive medical care or a referral to a maternal-fetal medicine specialist is not necessary
(H. E. Jones et al., 2014).
Despite the importance of PNC for optimizing the health of mothers and neonates,
receiving inadequate PNC is common in women with OUD (Heil et al., 2011) and preconception
substance use has a negative association with healthcare utilization during pregnancy
(Kotelchuck et al., 2017; Schempf & Strobino, 2008). Inadequate care is likely due to a variety of
factors, including perceptions of stigma and discrimination from and poor communication with
healthcare providers (Alexander et al., 2020; Frazer et al., 2019; Kuo et al., 2013). Finding ways
to improve PNC utilization, perhaps through more higher quality patient-centered care, could
have major implications for the mother-infant dyad affected by maternal OUD.
An alternative model to individual PNC that may benefit women with OUD, is groupbased PNC, such as CenteringPregnancy. The CenteringPregnancy model brings women of
similar gestational ages together, where they receive one-on-one assessments with a clinician
and engage in group discussions on topics related to their particular stage of pregnancy
(Massey et al., 2006). This patient-centered group care model bundles the medical assessment
of traditional PNC with comprehensive prenatal health education, consultation, and peer support
facilitated by a credentialed health care provider within a group environment (Rising, 1998).
Data on the effectiveness of group PNC among women with OUD, however, is lacking; research
is required for establishing group PNC as an evidence-based model for this patient population.
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Though it may be beneficial as it can provide continuity of care, build trust, and allow access to
a similar group of women who are at varying points along the recovery process.
MATER’s nursing department coordinates PNC for all pregnant individuals receiving
treatment at its programs. The default since 2019 has been to enroll pregnant individuals into
the CenteringPregnancy program, with the ability to opt out and engage in traditional prenatal
are at MATER’s affiliated academic medical center. Both are provided by the same providers,
however CenteringPregnancy ensures the pregnant person sees the same provider at each visit
versus rotating providers in the traditional PNC clinic. Pregnant women who have preferred
prenatal care providers at other institutions are encouraged to continue that relationship,
although the nursing department’s ability to coordinate care is diminished.
Another service that may benefit perinatal women with OUD is one that involves doulas,
non-clinical professionals who provide physical, emotional and informational support to mothers
before, during and after childbirth, including continuous labor support (DONA International, n.d.).
Doula services are associated with improved birth outcomes (lower C-section and preterm birth
rates) and higher rates of breastfeeding initiation (Bohren et al., 2017; Campbell et al., 2006).
Doula care services have also been studied in under-resourced communities, including
Medicaid recipients, and similar benefits have been reported (Thomas et al., 2017). Doula
access may also mitigate the effects of social determinants of health through addressing health
literacy and social support needs (Kozhimannil et al., 2016).
Through collaboration with the Maternity Care Coalition and the City of Philadelphia’s
Doula Program, MATER has facilitated a referral relationship matching pregnant and early postpartum women in treatment with a doula to facilitate additional support for the maternal-infant
dyad. The Doulas of this program are trained in SUD treatment and trauma-informed care,
providing services such as emotional support, referrals for physical items such as cribs and car
seats, instruction on positions to reduce discomfort during labor, breastfeeding support, and
advocacy for women in either their own or their child’s healthcare.
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Well Child Care
Routine well child care (WCC) is an important component of healthcare for all children.
WCC visits provide a critical opportunity for clinicians to assess family dynamics, diagnose and
prevent illness and injury, evaluate child growth and development, and provide anticipatory
guidance to optimize child outcomes (Committee on Practice and Ambulatory Medicine &
Workgroup, 2017). Current research, however, suggests that the delivery of routine WCC for
children affected by maternal OUD could be improved.
First, this population may be receiving inadequate WCC. Compared with the general
population, children with intrauterine opioid exposure are 50% less likely to receive adequate
WCC through the first two years of life (Goyal et al., 2020). Though they do receive timely
immunizations and lead screening (Goyal et al., 2020). Second, mothers in treatment for OUD
have reported limited family-centered care for their children during WCC visits. In a qualitative
study of mothers in treatment with OUD, only about half reported that their child’s provider
“always” knew their child’s medical history, listened carefully, clearly explained things and
respected the mother (Short et al., 2019), proportions well below data reported elsewhere
(AHRQ 2019). These perceptions of care may impact maternal trust and engagement in care,
perceptions of stigmatization, and satisfaction with care, and lead to less healthcare utilization
and ultimately, compromised child health.
Innovative approaches in the delivery of WCC for young children of mothers with OUD
may be needed to address these gaps in care and improve perceptions. Future attempts to
refine care may consider health care models that highlight aspects of WCC that mothers value,
which include a personalized mother-provider relationship, positive communication with the
health care team, and provider support for the mother’s OUD treatment and recovery (Short et
al., 2021). Group-based WCC is one approach that MATER has just begun using as part of
OUD treatment. Group WCC visits allow for increased time with pediatricians, peer-to-peer
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interaction, and more in-depth discussion of relevant topics (DeLago et al., 2018; Johnston et
al., 2017; Mittal, 2011). The provision of WCC at the site of maternal OUD treatment should also
be considered as the integration within the treatment program could potentially increase WCC
convenience, reduce stigma, and provide a unique opportunity for coordination of other services
for mother-child dyad. Additionally, women in treatment for OUD may be uniquely positioned for
this care model based on their frequent (e.g., daily) treatment visits and familiarity with group
therapy and programming. Addiction education tailored towards the needs of mothers with OUD
and their children may also be beneficial for clinics providing WCC to this population. Clinical
providers, including trainees, have reported negative feelings, such as frustration, stress,
burnout, and disconnect (Murphy-Oikonen et al., 2010; Romisher et al., 2018), as well as
discomfort with discussing mothers’ substance use and trauma histories (Schiff et al., 2017).

Supporting Staff
Staff care and support is one of the most unrecognized but essential elements of SUD
treatment. Staff are at risk for secondary trauma, burnout, and emotional stress. Mediating
these factors and prioritizing staff wellbeing is unconventional in the U.S. health care system.
However, addressing these issues stands to improve patient care and safety, therapeutic
outcomes, longevity in terms of staff turnover, and communication. Mindfulness Dialogue for
Life (MDfL) is a program implemented at MATER to improve leadership and staff
communication and workplace satisfaction. MDfL trains leaders to have more courageous
conversations and to think outside the box for enhanced treatment processes and employee
support. Weekly hour-long sessions of MDfL allow employees to meditate together, to process
the daily stress of life and work, to envision the job they want, and to make changes that reduce
their stress at work. Additionally, staff are supported to take Mindfulness Based Stress
Reduction (MBSR) and MATER pays the tuition for any staff that desires to take introductory or
graduate courses in mindfulness-based practice. We have found that with 40% of staff

Comprehensive Response for Parents with OUD

20

participation in MDfL and MBSR there are notable changes in the nature of the workplace and
decreases in anxiety associated with a high stress job such as SUD treatment (Abatemarco et
al., 2021).
At many residential treatment programs, including MATER’s residential facility, 24-hour
staffing is provided by employees with high-school diplomas. Recognizing the need for career
development for such staff, to increase opportunities for job advancement and financial mobility,
and to enhance the therapeutic community MATER has begun a community health worker
training and certification program. Small cohorts of staff, particularly 24-hour residential staff and
parent child center staff, engage in 16 weeks of asynchronous and synchronous training during
work hours. Upon successful completion, the staff member receives credentialing as a
community health worker. As a result, there is less disparity in education and behaviors across
the program’s staff and an overall elevation in the standard of care.

Other Unmet Needs
There are many additional needs that are often unmet for pregnant and parenting
women with OUD. Nicotine use, particularly cigarette smoking, is highly prevalent in this
population with upwards of 90% of individuals reporting daily smoking (Akerman et al., 2015).
Research on treating tobacco use disorder in this population is limited, but interactions between
nicotine and opioids point to some biological reasons why quitting smoking is difficult for women
with OUD (Kranzler et al., 2020; Oncken et al., 2019). Contingency management is an effective
intervention, but is underutilized (Hand, Ellis, et al., 2017; Tuten et al., 2012). MATER integrates
nicotine replacement therapy and smoking cessation counseling into standard care, with
particular emphasis during residential treatment.
Drug use practices, like injecting drugs, or behaviors associated with drug use, like sex
work, increase risk of contracting hepatitis, HIV, and sexually transmitted diseases. With
advances in antiviral medications for Hepatitis C and HIV, integration of these services into
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OUD treatment can significantly reduce these negative health outcomes. At MATER, routine
and on-demand testing for these communicable diseases is incorporated into standard care.
MATER has partnerships with organizations that provide treatment for HIV and Hepatitis C,
which involve inviting providers into MATER’s facility and coordinating delivery of medication as
part of SUD treatment. Similarly, integrating on-demand sexual and reproductive health services
can help with preventing and treating sexually transmitted diseases and facilitating access to
family planning assistance (Heil et al., 2016). MATER achieves this through its relationship with
its affiliation with the academic medical institution’s department of obstetrics & gynecology.
Food insecurity can also be common due to poverty, lack of access to reliable sources of
healthy food, and less than adequate welfare benefits (Rose-Jacobs, Trevino-Talbot, Vibbert, et
al., 2019). Food insecurity during pregnancy is associated with increased risk of neonatal
abstinence syndrome requiring pharmacotherapy for treatment (Rose-Jacobs, Trevino-Talbot,
Lloyd-Travaglini, et al., 2019). Providing this aid could be outside the scope or budget or
programs, requiring partnerships with local food pantries or similar charities. Of note, providing
meals during prenatal care visits is a component of CenteringPregnancy, which can help
provide at least temporary nutrition assistance.

Conclusions
Addressing OUD among pregnant and parenting women requires a comprehensive
approach that is sensitive to the specific needs of this population. With trauma histories nearly
ubiquitous among women with OUD, approaches must be trauma-responsive to facilitate
healing and prevent re-traumatization. An approach that uses compassion as a foundation,
which can be facilitated through mindfulness practice among staff and as a therapeutic modality,
can achieve this goal. Co-location and integration of multiple support services into OUD
treatment, under the same guiding principles, aids in ensuring a continuity of experience and

Comprehensive Response for Parents with OUD

22

can prevent traumatization from engagements in traditional care settings. Lastly, supporting
staff with meaningful self-care opportunities, can help reduce compassion fatigue that can drive
suffering and burnout. The field of OUD treatment for pregnant and parenting women has
substantially evolved over the last several decades. Its continued evolution toward whole-family
health care is necessary to prevent intergenerational transmission of SUDs.
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Figure 1. A visual representation of the transdisciplinary team at MATER and its activities.
Navigation guides engagement in medications for opioid use disorder (mOUD) and therapy and
their interaction at the core, with additional services integrated and coordinated as individually
appropriate.
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